[BTX] BioTime, Inc.

Overview

Type of security: Stock

Sector: Health Care

Industry: Biotechnology: Biological Products (No Diagnostic Substances)

Market Capitalization:

Exchange: AMEX

The data is delayed by 15 minutes.

 

Price: 3.82 Change: 0.06 (1.46%)
Ext. hours: Change: 0 (0%)

chart BTX

Refresh chart

Strongest Trends Summary For BTX

BTX is in the long-term down -77% below S&P in 4 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart

 

Description: BioTime, Inc., a biotechnology company, is engaged in the research and product development in the field of regenerative medicine. The company primarily focuses on regenerative medicine, which refers to therapies based on human embryonic stem cell and induced pluripotent stem cell technology designed to rebuild cell and tissue function lost due to degenerative disease or injury. It develops and markets research products in the field of stem cells, including an array of proprietary PureStem cell lines and associated ESpan culture media, cGMP-capable human embryonic stem cell lines, and differentiation kits, as well as offers Hextend, a blood plasma volume expander to treat hypovolemia in surgery, emergency trauma treatment, and other applications. The company is developing Renevia, a biocompatible, implantable hyaluronan, and collagen-based matrix for cell delivery in human clinical applications; and stem cell-based therapies for retinal and neurological disorders. It also develops HyStem hydrogels, such as ReG

See how to gain 20% in 14 sec with TrendsInvesting

Fundamental Ratios
Shares Outstanding EPS-0.02 EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters 14.18% Sales Growth - Q/Q-32.69% P/E
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA-55.21% ROE-66.91% ROI-143.23%
Current Ratio3.48 Quick Ratio3.44 Long Term Debt/Equity0.03 Debt Ratio0.14
Gross Margin82.19% Operating Margin-974.95% Net Profit Margin-707.22% Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities300 K Cash From Investing Activities Cash From Operating Activities-230 K Gross Profit70 K
Net Profit80 K Operating Profit80 K Total Assets700 K Total Current Assets670 K
Total Current Liabilities440 K Total Debt80 K Total Liabilities440 K Total Revenue140 K
Technical Data
High 52 week2.79 Low 52 week0.86 Last close0.92 Last change-7.08%
RSI34.54 Average true range0.08 Beta0.84 Volume263.3 K
Simple moving average 20 days-16.52% Simple moving average 50 days-14.52% Simple moving average 200 days-27.4%
Performance Data
Performance Week-11.55% Performance Month-22.7% Performance Quart-23.98% Performance Half-17.13%
Performance Year-59.83% Performance Year-to-date0.76% Volatility daily3.99% Volatility weekly8.93%
Volatility monthly18.29% Volatility yearly63.36% Relative Volume328.96% Average Volume472.06 K
New High New Low

News

2019-11-13 08:06:58 | Edited Transcript of BTX earnings conference call or presentation 12-Nov-19 9:30pm GMT

2019-08-09 17:00:23 | Edited Transcript of BTX earnings conference call or presentation 8-Aug-19 8:30pm GMT

2019-08-08 16:05:00 | BioTime Reports Second Quarter 2019 Financial Results and Provides Business Update

2019-07-31 08:00:00 | BioTime Announces Name Change to Lineage Cell Therapeutics

2019-07-25 10:33:02 | BioTime BTX May Report Negative Earnings: Know the Trend Ahead of Q2 Release

2019-07-11 08:00:00 | BioTime Initiates Dosing in Phase I/IIa Clinical Study of OpRegen for Treatment of Dry-AMD Utilizing Orbit Subretinal Delivery System

2019-07-02 16:15:00 | BioTime Conducts Sale of Shares in OncoCyte Corporation

2019-06-24 06:27:18 | Should You Be Excited About BioTime, Inc.'s NYSEMKT:BTX 35% Return On Equity?

2019-06-17 01:23:22 | Is Forbuild SA’s WSE:BTX 16% ROCE Any Good?

2019-05-22 08:00:00 | BioTime Announces Appointment of General Counsel

2019-05-15 02:06:35 | Don't Sell Forbuild SA WSE:BTX Before You Read This

2019-05-14 11:23:15 | BioTime BTX Q1 2019 Earnings Call Transcript

2019-05-13 09:13:01 | Achillion ACHN Reports Wider-Than-Expected Loss in Q1

2019-05-10 13:48:59 | Edited Transcript of BTX earnings conference call or presentation 9-May-19 8:30pm GMT

2019-05-10 08:00:00 | BioTime Awarded $2.5 Million Grant from the Israel Innovation Authority for Continued Development of OpRegen®

2019-05-09 18:35:10 | BioTime BTX Tops Q1 Earnings and Revenue Estimates

2019-05-09 17:30:27 | BioTime: 1Q Earnings Snapshot

2019-05-09 16:05:00 | BioTime Reports First Quarter 2019 Financial Results and Provides Business Update

2019-05-06 08:00:00 | BioTime Announces Issuance of U.S. Patent for Method of Reducing Cavitation in Patients with Acute Spinal Cord Injury

2019-05-03 08:00:00 | BioTime to Report First Quarter 2019 Financial Results and Provide Business Update on May 9, 2019

2019-05-02 10:32:02 | Will BioTime BTX Report Negative Q1 Earnings? What You Should Know

2019-05-02 08:00:00 | BioTime Presents Updated Data from OpRegen® Phase I/IIa Clinical Study at the Association for Research in Vision and Ophthalmology Annual Meeting

2019-04-27 11:44:12 | The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trial Readouts And IPOs

2019-04-26 08:00:00 | BioTime to Present SCiStar Clinical Study Top-Line Data at the 26th Annual American Society for Neural Therapy and Repair Conference

2019-04-24 14:17:56 | Did Changing Sentiment Drive BioTime's NYSEMKT:BTX Share Price Down A Worrying 58%?

2019-04-16 08:00:00 | BioTime to Present Data from OpRegen® Phase I/IIa Clinical Study at the Association for Research in Vision and Ophthalmology Annual Meeting ARVO 2019

2019-04-12 09:00:01 | BioTime BTX Upgraded to Strong Buy: Here's What You Should Know

2019-04-02 10:38:02 | Top Ranked Momentum Stocks to Buy for April 2nd

2019-03-18 08:00:00 | BioTime to Present at Oppenheimer & Co. 29th Annual Healthcare Conference on March 20, 2019

2019-03-14 23:50:58 | Edited Transcript of BTX earnings conference call or presentation 14-Mar-19 8:30pm GMT

2019-03-14 17:02:21 | BioTime: 4Q Earnings Snapshot

2019-03-14 16:05:00 | BioTime Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Business Update

2019-03-11 08:00:00 | BioTime Announces Closing of Acquisition of Asterias Biotherapeutics Creating Leading Cell Therapy Company

2019-03-07 08:00:00 | BioTime to Report Fourth Quarter and Full Year 2018 Financial Results on March 14th, 2019

2019-03-04 08:00:00 | BioTime to Present at the 14Th Annual Scientific Meeting of the Association for Ocular Pharmacology and Therapeutics AOPT 2019 on March 10, 2019

2019-02-26 08:00:00 | BioTime to Present New Data From OpRegen® and Vision Restoration Programs at the Association for Research in Vision and Ophthalmology Annual Meeting ARVO 2019

2019-02-22 07:55:00 | Consolidated Research: 2019 Summary Expectations for Walmart, W.R. Grace, BioTime, Genesee & Wyoming, Northrop Grumman, and Versum Materials — Fundamental Analysis, Key Performance Indications

2019-02-14 08:00:00 | BioTime Provides Business Update Including Information on AgeX, OncoCyte and Asterias

2019-02-05 09:00:00 | Most Intriguing Companies on the New LD Micro Index

2019-01-30 08:00:00 | Today's Research Reports on Trending Tickers: BioTime and Zynerba Pharmaceuticals

2019-01-30 08:00:00 | BioTime Inc. Affiliate Company OncoCyte Corporation Reports Successful Results With DetermaVu™ Diagnostic Test for Lung Cancer

2019-01-09 08:00:00 | AgeX Therapeutics Publishes Data in Peer-Reviewed Journal to Advance Potential Cell Therapy AgeX-BAT1 for Type II Diabetes and Obesity

2019-01-07 08:00:00 | BioTime Enters Into Exclusive Agreement With Orbit Biomedical Ltd. to Access Innovative Device for the Sub-Retinal Delivery of OpRegen® Cells for the Treatment of Dry-AMD

2019-01-04 08:00:00 | BioTime Announces Management Changes Concurrent With Participation at 2019 J.P. Morgan Healthcare Conference and 2019 Biotech Showcase

2019-01-02 08:00:00 | BioTime to Present at 2019 Biotech Showcase Investor Conference on January 7, 2019

2019-01-02 07:00:00 | AgeX Therapeutics to Present at Biotech Showcase 2019

2018-12-23 11:38:33 | BioTime, Inc. BTX: Are Hedge Funds Right About This Stock?

2018-12-04 08:00:00 | BioTime Announces Publication of Positive Preclinical Results Utilizing Proprietary HyStem® Platform in Ischemic Stroke

2018-12-03 07:55:00 | New Research: Key Drivers of Growth for Q2, BioTime, Verastem, Fair Isaac, Ulta Beauty, and Chimerix — Factors of Influence, Major Initiatives and Sustained Production

2018-11-29 08:00:00 | AgeX Therapeutics, Inc. to Present Keynote Address at Advanced Stem Cell & Regenerative Medicine 2018 Conference